THY1 and glomerulonephritis: Contrary to everolimus, i.v. administration of a single bolus dose of BMDSCs one week after induction of glomerulonephritis failed to improve renal injury, although it lowered the expression of renal T cells and IL-17, suggesting that the reduction in immune cell infiltration might not necessarily translate to a reduction in renal injury in anti-Thy1-induced nephritis in rats.